Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare, serious condition that can lead to excessive bleeding in fetuses and newborns. It is caused by a mismatch between an expectant mother and her fetus in a specific human platelet antigen, most commonly HPA-1. There is currently no approved therapy for the prevention or treatment of patients with FNAIT.
The stock we are bringing to your attention today is that of Rallybio Corp. (RLYB), a clinical-stage biotechnology company developing therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.